Enveda Biosciences, an AI-driven drug discovery company, has raised $311 million in Series E funding. The company is advancing three AI-designed drugs into human trials for immune diseases and obesity. The funding will support further clinical development and strategic partnerships.
TL;DR
- Enveda Biosciences raises $311 million in Series E funding to advance its AI-designed drug pipeline.
- The company has three drugs in human trials, targeting immune diseases and obesity.
- Funding will support clinical trials and strategic partnerships to validate and capitalize on its drug candidates.
What happened
Enveda Biosciences, a Colorado-based AI drug discovery company, has secured $311 million in Series E financing. This sum is comparable to some of the largest initial public offerings in the biotechnology sector this year. The funding round was led by Catalio Capital Management and included 16 other backers, such as Surveyor Capital, T. Rowe Price, Lux Capital, and a sovereign wealth fund.
Enveda uses AI to identify and predict the structure and function of molecules in plants and microbes. The company's chemists then develop the most promising molecules into drug prospects. Enveda has 17 programs currently under evaluation, with three drugs already in human testing. The company previously raised over $530 million in venture backing, including a $150 million Series D round in 2025.
Why it matters
This funding will enable Enveda to continue advancing its drug pipeline through clinical trials. The company's AI-driven approach has the potential to identify novel drug candidates more efficiently than traditional methods. For developers and startups, this highlights the growing intersection of AI and biotechnology, offering new avenues for drug discovery and development.
For investors, Enveda's success could demonstrate the viability of AI in drug discovery, potentially attracting more funding to the sector. However, the company's strategy of putting multiple drugs into the clinic and partnering strategically at the right time will be crucial for its long-term success. The competitive landscape in biotechnology is fierce, and Enveda will need to prove the efficacy of its AI-designed drugs to stand out.
Key facts
- Enveda Biosciences raised $311 million in Series E funding, according to the company's announcement.
- The funding round was led by Catalio Capital Management and included 16 other backers, such as Surveyor Capital, T. Rowe Price, Lux Capital, and a sovereign wealth fund.
- Enveda has three drugs in human trials: ENV-294 for atopic dermatitis, ENV-308 for obesity, and ENV-6949 for inflammatory bowel disease.
- ENV-294 is a 'molecular glue' that showed potential to reduce eczema symptoms in a small, early clinical trial.
- ENV-308 is a pill designed to mimic the effects of exercise, targeting obesity and weight loss maintenance.
- ENV-6949 targets the TL1A pathway, a popular approach to treat inflammatory bowel disease.
- Enveda has 17 programs currently under evaluation, with three drugs already in human testing.
- The company previously raised over $530 million in venture backing, including a $150 million Series D round in 2025.
Context
Enveda Biosciences is part of a growing trend of companies using AI to revolutionize drug discovery. Traditional methods of drug discovery are time-consuming and expensive, often taking over a decade and costing billions of dollars to bring a single drug to market. AI has the potential to streamline this process by analyzing vast amounts of data to identify promising drug candidates more quickly and efficiently.
The success of Enveda and similar companies could pave the way for more AI-driven innovations in the biotechnology sector. As AI continues to advance, its applications in drug discovery and development are likely to expand, offering new opportunities for startups and investors alike. However, the competitive landscape in biotechnology is fierce, and companies like Enveda will need to demonstrate the efficacy of their AI-designed drugs to succeed in this highly regulated and challenging market.